Eqis Capital Management Inc. Buys Shares of 5,131 PerkinElmer, Inc. (NYSE:PKI)

Eqis Capital Management Inc. purchased a new position in PerkinElmer, Inc. (NYSE:PKI) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 5,131 shares of the medical research company’s stock, valued at approximately $350,000.

Several other large investors have also added to or reduced their stakes in PKI. Levin Capital Strategies L.P. raised its stake in PerkinElmer by 61.9% in the first quarter. Levin Capital Strategies L.P. now owns 980,463 shares of the medical research company’s stock worth $56,926,000 after buying an additional 374,761 shares in the last quarter. Chevy Chase Trust Holdings Inc. raised its stake in PerkinElmer by 3.0% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 94,643 shares of the medical research company’s stock worth $5,495,000 after buying an additional 2,759 shares in the last quarter. Credit Suisse AG raised its stake in PerkinElmer by 6.5% in the first quarter. Credit Suisse AG now owns 108,618 shares of the medical research company’s stock worth $6,306,000 after buying an additional 6,665 shares in the last quarter. Swiss National Bank raised its stake in PerkinElmer by 0.8% in the first quarter. Swiss National Bank now owns 181,200 shares of the medical research company’s stock worth $10,520,000 after buying an additional 1,400 shares in the last quarter. Finally, Morgan Stanley raised its stake in PerkinElmer by 10.5% in the first quarter. Morgan Stanley now owns 272,720 shares of the medical research company’s stock worth $15,834,000 after buying an additional 25,976 shares in the last quarter. 91.47% of the stock is currently owned by institutional investors.

Shares of PerkinElmer, Inc. (NYSE PKI) traded down 0.30% on Friday, hitting $63.47. The stock had a trading volume of 403,207 shares. PerkinElmer, Inc. has a 52 week low of $45.35 and a 52 week high of $70.16. The company has a 50-day moving average of $66.79 and a 200 day moving average of $61.18. The company has a market capitalization of $7.00 billion, a price-to-earnings ratio of 19.14 and a beta of 0.75.

PerkinElmer (NYSE:PKI) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. PerkinElmer had a net margin of 16.80% and a return on equity of 13.44%. The business had revenue of $547 million during the quarter, compared to the consensus estimate of $554.14 million. During the same quarter in the prior year, the firm earned $0.67 EPS. The business’s revenue was up 2.0% on a year-over-year basis. On average, equities research analysts predict that PerkinElmer, Inc. will post $2.89 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 10th. Shareholders of record on Friday, October 20th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.44%. The ex-dividend date is Thursday, October 19th. PerkinElmer’s dividend payout ratio (DPR) is presently 8.46%.

TRADEMARK VIOLATION WARNING: “Eqis Capital Management Inc. Buys Shares of 5,131 PerkinElmer, Inc. (NYSE:PKI)” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.com-unik.info/2017/08/19/5131-shares-in-perkinelmer-inc-nysepki-acquired-by-eqis-capital-management-inc-updated-updated-updated.html.

A number of equities research analysts have recently commented on PKI shares. Piper Jaffray Companies raised their price target on PerkinElmer to $80.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 25th. Morgan Stanley reissued an “overweight” rating and issued a $79.00 target price (up previously from $73.00) on shares of PerkinElmer in a research report on Monday, July 10th. Zacks Investment Research raised PerkinElmer from a “hold” rating to a “buy” rating and set a $74.00 target price on the stock in a research report on Tuesday, August 1st. Evercore ISI reissued an “in-line” rating and issued a $68.00 target price (up previously from $62.50) on shares of PerkinElmer in a research report on Thursday, June 22nd. Finally, Citigroup Inc. lifted their target price on PerkinElmer from $67.00 to $74.00 and gave the company a “buy” rating in a research report on Monday, August 7th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company’s stock. PerkinElmer presently has an average rating of “Hold” and an average target price of $67.00.

In other news, insider Andrew Okun sold 4,358 shares of the company’s stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $65.00, for a total transaction of $283,270.00. Following the sale, the insider now directly owns 16,799 shares in the company, valued at approximately $1,091,935. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Peter Barrett sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $63.22, for a total transaction of $632,200.00. Following the sale, the director now owns 29,200 shares in the company, valued at $1,846,024. The disclosure for this sale can be found here. 2.20% of the stock is owned by corporate insiders.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

What are top analysts saying about PerkinElmer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PerkinElmer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit